Alpine Immune Sciences, Inc. Expected to Post Q1 2023 Earnings of ($0.50) Per Share (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. (NASDAQ:ALPNGet Rating) – Oppenheimer issued their Q1 2023 EPS estimates for shares of Alpine Immune Sciences in a research report issued to clients and investors on Wednesday, June 1st. Oppenheimer analyst M. Breidenbach anticipates that the biotechnology company will post earnings per share of ($0.50) for the quarter. Oppenheimer also issued estimates for Alpine Immune Sciences’ Q2 2023 earnings at ($0.50) EPS, Q3 2023 earnings at ($0.52) EPS and Q4 2023 earnings at ($0.54) EPS.

Several other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 22nd. Wedbush reissued an “outperform” rating and set a $22.00 price objective on shares of Alpine Immune Sciences in a research report on Tuesday, May 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of Alpine Immune Sciences in a report on Friday, May 13th.

Shares of ALPN opened at $9.04 on Friday. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.02. The business’s 50-day moving average is $8.63 and its 200-day moving average is $9.60. Alpine Immune Sciences has a fifty-two week low of $6.00 and a fifty-two week high of $14.40.

Alpine Immune Sciences (NASDAQ:ALPNGet Rating) last released its quarterly earnings data on Thursday, May 12th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06). Alpine Immune Sciences had a negative return on equity of 46.87% and a negative net margin of 139.41%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Barclays PLC grew its holdings in Alpine Immune Sciences by 223.1% in the 3rd quarter. Barclays PLC now owns 4,747 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 3,278 shares during the last quarter. Citigroup Inc. grew its holdings in Alpine Immune Sciences by 184.0% in the 4th quarter. Citigroup Inc. now owns 3,766 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 2,440 shares during the last quarter. Bank of America Corp DE grew its holdings in Alpine Immune Sciences by 46.7% in the 4th quarter. Bank of America Corp DE now owns 4,944 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 1,573 shares during the last quarter. Strs Ohio acquired a new stake in Alpine Immune Sciences in the 4th quarter valued at approximately $76,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Alpine Immune Sciences by 23.4% during the 1st quarter. JPMorgan Chase & Co. now owns 8,947 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 1,697 shares in the last quarter. 77.00% of the stock is currently owned by hedge funds and other institutional investors.

Alpine Immune Sciences Company Profile (Get Rating)

Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.

Featured Articles

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.